Gain Therapeutics (GANX) enters $50M at-the-market equity offering with Oppenheimer

Gain Therapeutics, Inc.

Equity Distribution Agreement allows sale of up to $50M in common stock via Oppenheimer as agent.
Oppenheimer will receive a 3.0% commission on gross proceeds; company also reimburses certain expenses.
Sales will be made under existing shelf registration statement (Form S-3, effective June 1, 2022).
Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
Shares offered through Nasdaq or other trading market; no escrow or trust arrangement for proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.